Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the thirteen analysts that are currently covering...
MarketBeat·19h ago
More News
GSK Gets EU Approval for Expanded Use of Nucala in COPD
GSK secures EU approval for Nucala, an add-on maintenance treatment for chronic obstructive pulmonary disease in adults.
Zacks·3d ago
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates
BMY beats Q4 earnings and revenue estimates as its Growth Portfolio jumps 16%, lifting shares despite continued declines in legacy drugs.
Zacks·5d ago
HC Wainwright Predicts Immunocore FY2030 Earnings
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) - Analysts at HC Wainwright issued their FY2030 earnings estimates for shares of Immunocore in a research note issued to investors on...
MarketBeat·5d ago
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View
Novo Nordisk beats Q4 earnings and sales estimates, but shares slide after management forecasts a 5-13% decline in 2026 sales and operating profit.
Zacks·6d ago
NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study
Novo Nordisk reports that CagriSema beats semaglutide at HbA1c reduction and weight loss in a 68-week phase III diabetes study, with no weight-loss plateau.
Zacks·7d ago
Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU
ACAD expects a negative CHMP opinion on trofinetide marketing application for Rett syndrome, likely delaying a potential EU approval.
Zacks·7d ago
Immunocore (NASDAQ:IMCR) Cut to "Hold" at Wall Street Zen
Wall Street Zen lowered shares of Immunocore from a "buy" rating to a "hold" rating in a report on Saturday...